Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery and development teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. Learn more about Genmab

GENMAB INVESTORPORTAL

Genmab is implementing electronic shareholder communications. To register your email address for electronic communications, log on to the InvestorPortal.

Features
Post ASH Seminar
 Visit the investor site

Arzerra Wins Galien Prize as Year’s Best Medicine in the Netherlands

The Galien prize, awarded each year in the Netherlands for the most innovative and important new medicine on the market has been won by Arzerra (ofatumumab). Arzerra is now in the running for the International Prix Galien, considered the pharmaceutical industry’s equivalent to the Nobel Prize. For more information on the Prix Galien visit http://www.prixgalien.com/en/01/introduction.htm.

Genmab's cGMP Biologics Manufacturing Facility is Available

View the Updated Virtual Lab Tour of Genmab's R&D Facilities

Legal Notice
Use of this Site is subject to Important Legal Terms, which you are requested to read prior to proceeding.
© 2011 Genmab A/S